Zantac 75 slated for first-quarter launch following Dec. 19 approval by FDA.
This article was originally published in The Tan Sheet
Executive Summary
WARNER-LAMBERT BANKING ON ZANTAC's Rx "LEADERSHIP" POSITION to propel Zantac 75 into the competitive OTC H2 antagonist market, the company indicated in a same-day announcement of FDA's approval of the drug for the treatment of heartburn on Dec. 19. Zantac 75 is the third Rx-to-OTC switch H2 antagonist to clear FDA; the ranitidine HCl 75 mg product is slated to launch in the first quarter.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning